Immunitas Therapeutics
PrivateLast Round
Series B
Aug 18, 2021
Total Funding Raised
$97M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Immunitas Therapeutics operates in Healthcare & Life Sciences and is based in Waltham, Massachusetts. Its latest recorded funding round was a Series B round in August 2021.
Immunitas Therapeutics is a biotechnology company that develops innovative therapeutics aimed at treating patients with complex cancers and autoimmune diseases through a single-cell genomics platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immunitas Therapeutics Comparables
Compare Immunitas Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tizona Therapeutics | 81% | |
| Immune-Onc Therapeutics | 80% | |
| Coherus BioSciences Inc | 76% |
For institutional investors. Book with your work email.
Immunitas Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 18, 2021 | ||||
| Series A | Nov 21, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Immunitas Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Agent Capital | Series B |
| 120 Capital | Series B |
| Dean Capital Investments Management | Series A |
| Mirae Asset | Series B |
| M Ventures | Series A, Series B |
| BrightEdge | Series B |
| Medical Excellence Capital | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 93% MoM, reaching 2.3K.
- Jul 25, 2026
Monthly visitors grew 304% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 14, 2026
Immunitas Therapeutics develops the T cell-depleting autoimmune approach IMT-380, an anti-CD161 antibody candidate, and presents preclinical data on it on Oct 14th '26.
For institutional investors. Book with your work email.
Immunitas Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Immunitas Therapeutics's valuation, stock price, and market status.
Is Immunitas Therapeutics a public or private company?
Immunitas Therapeutics is a private company.
What is the current stock price of Immunitas Therapeutics?
Immunitas Therapeutics is a private company, so its shares have no public market price. Caplight tracks Immunitas Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Immunitas Therapeutics worth (valuation)?
Valuation information for Immunitas Therapeutics is not publicly available.
Can I buy Immunitas Therapeutics stock?
Immunitas Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Immunitas Therapeutics's last funding round?
Immunitas Therapeutics's most recent funding round was Series B on August 18, 2021.
Who are the main investors in Immunitas Therapeutics?
Key investors in Immunitas Therapeutics include Agent Capital, Leaps by Bayer.
Will Immunitas Therapeutics IPO soon?
No public IPO plans have been announced for Immunitas Therapeutics.
How can I track Immunitas Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Immunitas Therapeutics's shares on secondary markets.